Summary of Key Points Core Viewpoint - Chengda Biological Co., Ltd. has announced its share repurchase plan, which is aimed at employee stock ownership plans or equity incentives, but as of July 31, 2025, the company has not yet implemented this plan [1][3]. Trading Information - On August 5, 2025, Chengda Biological's stock closed at 28.58 yuan, with a slight increase of 0.28% - The trading volume was 21,900 shares, resulting in a total transaction value of 62.5655 million yuan - The net inflow of main funds was 2.6507 million yuan, accounting for 4.24% of the total transaction value - Retail investors had a net inflow of 702,900 yuan, representing 1.12% of the total transaction value, while speculative funds saw a net outflow of 3.3536 million yuan, making up 5.36% of the total transaction value [1][3]. Company Announcement - The share repurchase plan was first disclosed on June 19, 2025, with an implementation period from June 19, 2025, to June 18, 2026 - The expected repurchase amount is between 10 million yuan and 20 million yuan - The repurchase price will not exceed 38.00 yuan per share - As of July 31, 2025, the company has not repurchased any shares, with a total repurchase amount of 0 yuan and a shareholding proportion of 0% - The company will disclose the progress of the repurchase plan within the first three trading days of each month during the repurchase period [1].

Group 1 - The core point of the news is the personnel adjustment at Chengda Biological, with the resignation of the former board secretary Cui Jianwei and the appointment of Li Yeji as the new board secretary [1][3] - Cui Jianwei will continue to serve as a director, deputy general manager, and chief financial officer, indicating that his experience in financial and business management will still contribute to the company's strategic development [3] - Li Yeji, born in October 1992, has a strong educational background and extensive experience in investment banking and asset management, which may align with the company's future capital operation needs [3] Group 2 - The personnel change occurs against the backdrop of a significant shift in Chengda Biological's control structure, with the indirect controlling shareholder changing from the Liaoning State-owned Assets Supervision and Administration Commission to a state of no actual controller [3] - The new controlling shareholder, Shaoguan Gaoteng Enterprise Management Co., Ltd., gained control through board seat advantages, although this change did not directly lead to management turmoil [3] - Market analysis suggests that the new board secretary's investment banking background may be related to the company's future capital operation requirements [3]

证券时报·数据宝统计显示，已上市的589只科创板股中，最新收盘价较发行价平均溢价116.81%，其 中，收盘价较发行价溢价的有447只，溢价幅度最高的是上纬新材，最新收盘价较发行价溢价 4443.07%，热景生物、百利天恒、安集科技等紧随其后，分别溢价1105.04%、1102.27%、1087.29%。 最新收盘价较发行价出现折价的有141只，也即是破发。 科创板股最新收盘价较发行价平均溢价116.81%，其中，141股出现破发。 破发幅度最大的是万润新能，最新价较发行价折价78.95%，该股2022年9月29日上市，发行价为299.88 元，发行市盈率为75.25倍，行业平均市盈率为19.21倍，公司主要从事锂电池正极材料的研发、生产和 销售。 其次是ST帕瓦，该股2022年9月19日上市，最新价较发行价折价76.58%，发行价为51.88元，发行市盈率 为93.68倍，行业平均市盈率为29.25倍，公司主要从事新能源电池材料的研发、生产和销售。 成大生物最新价较发行价折价70.99%，天宜新材最新价较发行价折价65.45%，中科微至最新价较发行 价折价61.35%，康希诺最新价较发行价折价60.04%， ...

Core Viewpoint - Chengda Biological announced on August 4 that as of July 31, 2025, the company has not yet implemented its share repurchase plan and will choose to execute the plan based on market conditions [1] Summary by Relevant Categories - **Company Announcement** - Chengda Biological has released a statement regarding its share repurchase plan, indicating that it remains unimplemented as of the specified date [1] - The company plans to assess market conditions before proceeding with the share repurchase [1]

成大生物最新价较发行价折价71.07%，天宜新材最新价较发行价折价66.00%，康希诺最新价较发行价 折价61.65%，中科微至最新价较发行价折价61.65%，金迪克最新价较发行价折价57.21%。（数据宝） 科创板股破发幅度排名 科创板股最新收盘价较发行价平均溢价114.49%，其中，143股出现破发。 证券时报·数据宝统计显示，已上市的589只科创板股中，最新收盘价较发行价平均溢价114.49%，其 中，收盘价较发行价溢价的有445只，溢价幅度最高的是上纬新材，最新收盘价较发行价溢价 3686.03%，热景生物、安集科技、百利天恒等紧随其后，分别溢价1090.17%、1085.87%、1079.76%。 最新收盘价较发行价出现折价的有143只，也即是破发。 破发幅度最大的是万润新能，最新价较发行价折价79.04%，该股2022年9月29日上市，发行价为299.88 元，发行市盈率为75.25倍，行业平均市盈率为19.21倍，公司主要从事锂电池正极材料的研发、生产和 销售。 其次是ST帕瓦，该股2022年9月19日上市，最新价较发行价折价76.75%，发行价为51.88元，发行市盈率 为93.68倍，行业平 ...

Core Viewpoint - The collaboration between Chengda Biological and Zhongke Zhidong Taichu aims to establish an "AI + Vaccine Research Joint Laboratory" to enhance vaccine development through AI technology integration [1][3]. Group 1: Collaboration Details - The partnership focuses on four main areas: data integration and analysis platform construction, development of AI tools for vaccine research, establishment of a scientific service platform, and co-building industry influence through academic forums and promotional activities [2][3]. - Chengda Biological will provide research data and application scenarios, while Zhongke Zhidong Taichu will handle AI technology development and platform construction, retaining intellectual property rights for AI tools and models [1][2]. Group 2: Company Profiles - Chengda Biological is the world's largest producer of human rabies vaccines, with a market share that remains the highest globally, having distributed over 450 million doses across more than 30 countries [3]. - Zhongke Zhidong Taichu, a leading AI model company, aims to advance China's general artificial intelligence infrastructure and has developed the "Zhidong Taichu 3.0" model, which competes with international models like GPT-4o [3][4]. Group 3: Strategic Importance - The collaboration is seen as a significant step towards integrating AI technology into vaccine research, potentially leading to enhanced efficiency and innovation in the industry [2][5]. - Guangdong Minying Investment Co., Ltd. played a crucial role in facilitating this partnership, being a major investor in Zhongke Zhidong Taichu and the largest shareholder of Chengda Biological's parent company [5][6].

证券代码：688739 证券简称：成大生物 公告编号：2025-038 辽宁成大生物股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律 监管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做 出回购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务， 敬请广大投资者注意投资风险。 特此公告。 辽宁成大生物股份有限公司 一、回购股份的基本情况 公司于2025年6月19日召开第五届董事会第十九次会议，审议通过了《关于以 集中竞价交易方式回购公司股份方案的议案》。公司拟使用不低于人民币1,000万 元（含）且不超过人民币2,000万元（含）的超募资金以集中竞价交易方式回购公 司人民币普通股股票，用于实施员工持股计划或股权激励，回购股份的价格为不 超过人民币38.00元/股（含），回购股份期限为自公司董事会审议通过本次回购股 份方案之日起不超过12个月。具体内容详见公司于2025 ...

Group 1 - The core point of the article is that Chengda Biological has announced the progress of its share repurchase plan, stating that as of July 31, 2025, the company has not yet implemented this plan and will decide on the timing based on market conditions [2] - For the year 2024, Chengda Biological's revenue composition is entirely from biopharmaceuticals, accounting for 100.0% [2]

格隆汇8月4日丨成大生物(688739.SH)公布，截至2025年7月31日，公司尚未实施本次股份回购计划，公 司后续将根据市场情况择机实施本次回购计划。 ...

Core Viewpoint - The recent management change at Chengda Biological Co., Ltd. signifies a strategic shift towards a dual focus on capital and research and development, as the company faces challenges in the competitive vaccine market [3][9]. Management Change - On July 29, 2023, Chengda Biological announced the appointment of 33-year-old Li Yejiji as the new board secretary, replacing 47-year-old Cui Jianwei, who retains his roles as director, deputy general manager, and CFO [3][5]. - Li Yejiji's background in investment and capital markets contrasts with Cui Jianwei's extensive experience in finance and compliance, indicating a potential shift in the company's strategic direction [5][9]. Company Performance - Chengda Biological, established in 2002, was once a leader in the human rabies vaccine market, achieving a peak market capitalization of 33.6 billion yuan [6]. - However, since 2022, the company has faced declining prices for its core product, with the price of its freeze-dried human rabies vaccine dropping from 215 yuan to between 70 and 130 yuan per dose [6][8]. - The gross margin for the human rabies vaccine has decreased to 82.21%, reflecting the pressures from increased market competition and centralized procurement [6][8]. Financial Data - In the first quarter of 2025, Chengda Biological reported revenues of 358 million yuan, a year-on-year decline of 1.73%, and a net profit of 72 million yuan, down 25.53% [7][8]. - The company’s revenue from the human rabies vaccine was approximately 1.54 billion yuan, with a gross margin of 82.21%, showing a slight decrease compared to the previous year [7][8]. Future Outlook - The appointment of Li Yejiji is seen as a critical step for Chengda Biological to transition from a product-driven approach to a dual focus on capital and research and development [9]. - The company has 15 ongoing research projects, including significant vaccines that require substantial funding, indicating a need for effective capital management [9][10]. - The ability of the new management team to convert capital narratives into tangible performance will be crucial for the company's stock price and market perception [12].